

#4



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Furman et al.

Serial No.: 10/023,636

Group Art Unit: 1623

Filed: December 17, 2001

Examiner: Not Yet Assigned

For: DAPD Combination Therapy with Inosine Monophosphate Dehydrogenase Inhibitor

Assistant Commissioner for Patents
Washington, DC 20231

March 14, 2002


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publication listed on the accompanying Form PTO-1449A. A copy of the listed reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.


Respectfully submitted,


Josephine Young
Registration No. 48,308KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-4600 (Telephone)
404-572-5145 (Facsimile)



CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Josephine Young

Date: March 14, 2002